Table 1. Summary of Changes in 8th Edition.
Changes in anatomic stages (T, N, M) | |
Clarification of previously ambiguous definitions (T) | Maximum dimension of largest tumor is measured not adding satellite foci |
Multiple cancers are documented using (m) modifier | |
Satellite tumor nodules in skin should be separate from main mass to qualify T4b | |
Measurement of metastatic lymph node on pathology (N) | Pathologic staging of lymph node metastases uses only largest contiguous tumor deposit for pN |
Definition of distant metastasis (M) | pM0 is not valid category; cM0, cM1, and pM1 are used |
Clarification of post neoadjuvant therapy staging | |
After neoadjuvant therapy, ycTNM and ypTNM classification are used | |
Response to neoadjuvant chemotherapy is evaluated as complete response, partial response, and no response | |
Adoption of prognostic staging (Clinical and Pathologic Prognostic Stages) | |
Inclusion of biomarkers: tumor grade, hormone receptors, and HER2 | |
Inclusion of multigene panels (Oncotype DX) | |
Clinical Prognostic Stage is assigned to all patients regardless of type of therapy they receive | |
Pathologic Prognostic Stage is assigned to patients who receive surgery as initial treatment (excluding patients who receive neoadjuvant chemotherapy) |
M = metastasis, N = nodes, pN = pathologic N, T = tumor, TNM = tumor-node-metastasis